{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-054768","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.169306+00:00","generated_at":"2026-06-07T20:58:32.696177+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PDS Biotech appoints Lars Boesgaard as CFO; Matthew Hill resigns effective Dec 1, 2023","bullets":["CFO Matthew Hill resigned effective Dec 1, 2023 to pursue other opportunities; no disagreement with company.","Lars Boesgaard appointed CFO effective Dec 4, 2023; brings 25+ years healthcare finance experience.","Employment agreement: $420,000 annual salary, 40% performance bonus, 12-month severance, COBRA reimbursement.","Boesgaard receives inducement option for 200,000 shares vesting over four years."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-054768","json":"https://secwatch.observer/filing/0001140361-23-054768.json","markdown":"https://secwatch.observer/filing/0001140361-23-054768.md","text":"https://secwatch.observer/filing/0001140361-23-054768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123054768/0001140361-23-054768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123054768/ef20015466_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:58:32.696177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0614d57d81","claim":"Matthew Hill resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at PDS Biotechnology Corp.","evidence_excerpt":"On November 21, 2023, Matthew Hill submitted his resignation, effective December 1, 2023, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corporation (the “ Company ”) in order to pursue other professional endeavors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123054768/0001140361-23-054768-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"9c91e0809d","claim":"Lars Boesgaard was appointed as Chief Financial Officer at PDS Biotechnology Corp.","evidence_excerpt":"On November 28, 2023, the Company entered into an Executive Employment Agreement with Lars Boesgaard (the “ Employment Agreement ”), pursuant to which Mr. Boesgaard will assume the role of the Company’s Chief Financial Officer, effective as of December 4, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036123054768/0001140361-23-054768-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}